Visceral Fat and Oesophagitis: Causes and Treatment

Visceral fat and oesophagitis are more closely linked than many people realise. Visceral fat, the metabolically active fat stored deep within the abdominal cavity, can raise intra-abdominal pressure, weaken the lower oesophageal sphincter and allow stomach acid to irritate the oesophageal lining, causing inflammation known as oesophagitis. Research consistently identifies central adiposity as a stronger risk factor for gastro-oesophageal reflux disease (GORD) than overall body weight alone. This article explains the mechanisms involved, the symptoms to watch for, how oesophagitis is diagnosed and treated on the NHS, and what you can do to reduce visceral fat and protect your oesophageal health.

Can visceral fat put pressure on your oesophagus and cause inflammation?

Visceral fat raises intra-abdominal pressure, weakening the lower oesophageal sphincter and allowing acid to reflux into the oesophagus, causing inflammation. Central adiposity is a stronger risk factor for oesophagitis than overall BMI.

Visceral fat can raise intra-abdominal pressure in ways that contribute to oesophageal inflammation, though the mechanism is indirect rather than direct. Visceral fat is the metabolically active fat stored deep within the abdominal cavity, surrounding organs such as the stomach, liver and intestines.^[23][8] Unlike subcutaneous fat, which sits beneath the skin, visceral fat occupies a confined space and can raise intra-abdominal pressure significantly.

When intra-abdominal pressure increases, it pushes the stomach upward and can weaken the lower oesophageal sphincter (LOS), the muscular valve that normally prevents stomach acid from travelling back into the oesophagus.^[22] Once this barrier is compromised, acidic gastric contents can reflux into the oesophageal lining, which lacks the protective mucus layer found in the stomach. Repeated exposure to acid causes irritation and, over time, inflammation known as oesophagitis.

Observational and epidemiological research in gastroenterology literature consistently identifies central adiposity, particularly visceral fat accumulation, as a stronger risk factor for gastro-oesophageal reflux disease (GORD) and oesophagitis than overall body weight alone, though these associations may be influenced by confounding factors.^[5][3] This means that even individuals with a body mass index (BMI) in the normal range may develop reflux-related oesophageal inflammation if they carry excess visceral fat. Understanding this distinction is important for both prevention and treatment.

How does abdominal fat contribute to acid reflux and oesophagitis?

Abdominal fat drives reflux through mechanical pressure on the LOS and by secreting pro-inflammatory cytokines that may impair oesophageal mucosal recovery. It is also associated with hiatus hernia, which compounds reflux.

Abdominal fat contributes to acid reflux and oesophagitis through two main pathways: mechanical compression and metabolic effects. The mechanical pathway involves elevated intra-abdominal pressure, which pushes gastric contents upward against the LOS. This pressure is compounded when a person lies down, bends forward or wears tight clothing, all of which are common triggers for reflux symptoms.

The second pathway involves metabolic changes associated with visceral fat. Visceral fat is not inert tissue; it actively secretes pro-inflammatory cytokines, including tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6).^[6][7] These substances are associated with systemic low-grade inflammation, which may impair the integrity of the oesophageal mucosa and reduce its ability to recover from acid exposure, though the direct local mucosal effects remain an area of ongoing research. Some evidence also suggests that hormonal changes associated with visceral adiposity, including alterations in progesterone and other mediators, may influence smooth muscle tone including that of the LOS, though the precise endocrine mechanisms are not fully established.

A further complication is the association between central obesity and hiatus hernia, a condition in which part of the stomach protrudes through the diaphragm into the chest cavity. Hiatus hernia significantly worsens reflux by further disrupting the anti-reflux barrier. Observational data suggest that central adiposity is associated with a higher prevalence of hiatus hernia, creating a compounding cycle of reflux and oesophageal injury.^[5]

Collectively, these mechanisms explain why weight management, and specifically reduction of visceral fat, is a central component of GORD and oesophagitis management in UK clinical guidelines, including NICE CG184.^[1][3]

What are the symptoms of oesophagitis and when should you see a GP?

Oesophagitis typically causes persistent heartburn, regurgitation and dysphagia; see a GP if symptoms last several weeks or are uncontrolled by antacids. Dysphagia, unintentional weight loss or vomiting blood are red flags requiring prompt assessment.

Oesophagitis most commonly presents as a persistent burning sensation in the chest or throat, often described as heartburn, which tends to worsen after eating, when lying down or when bending over. Other typical symptoms include:

• Regurgitation of acidic or bitter fluid into the mouth or throat

• Dysphagia (difficulty swallowing), particularly with solid foods

• Odynophagia (pain on swallowing)

• Chest discomfort that may be mistaken for cardiac pain

• Chronic cough, hoarseness or a sensation of a lump in the throat

• Nausea or a feeling of fullness shortly after eating

Mild, infrequent heartburn is common and does not always require medical review. However, you should contact your GP if symptoms are persistent over several weeks, are not adequately controlled by over-the-counter antacids or medicines, or are having a significant impact on your daily life. You should also seek prompt GP assessment if symptoms are accompanied by unintentional weight loss, difficulty swallowing, vomiting blood, or passing black or tarry stools. These are red flag features that require timely assessment.

Dysphagia in particular warrants urgent review, as it may prompt referral under the NHS suspected cancer pathway in line with NICE NG12.^[4] Iron-deficiency anaemia and persistent vomiting are also features that should prompt prompt GP contact.

If you experience severe chest pain, particularly with breathlessness, sweating or pain radiating to the arm or jaw, call 999 immediately, as these may indicate a cardiac emergency rather than oesophageal disease. For urgent advice that does not require an emergency response, NHS 111 is available around the clock. Oesophagitis that is left untreated can progress to complications including Barrett's oesophagus, a precancerous change in the oesophageal lining, making timely GP review important.^[11][12]

How is oesophagitis diagnosed and treated on the NHS?

Oesophagitis is diagnosed via clinical history and gastroscopy where indicated, with PPIs such as omeprazole recommended as first-line treatment under NICE CG184. Surgical options such as laparoscopic fundoplication are available for severe or refractory cases.

Oesophagitis is typically diagnosed through a combination of clinical history and, where indicated, endoscopy. A GP will usually begin with a thorough symptom assessment and may initiate a trial of acid-suppressing medication. If symptoms persist, are atypical, or red flag features are present, referral for upper gastrointestinal endoscopy (gastroscopy) is arranged. Red flag features such as dysphagia may prompt urgent referral under the suspected cancer pathway per NICE NG12, while refractory but non-red-flag symptoms may lead to routine endoscopy referral. During gastroscopy, a thin flexible camera is passed through the mouth to visualise the oesophageal lining directly, allowing grading of inflammation and biopsy if needed.

NICE CG184 supports the use of proton pump inhibitors (PPIs) such as omeprazole or lansoprazole as first-line pharmacological treatment for GORD and oesophagitis.^[1][2] An initial full-dose PPI trial typically lasts four to eight weeks, after which a step-down or step-off approach may be considered depending on response.^[1][2] PPIs work by blocking the hydrogen-potassium ATPase enzyme in gastric parietal cells, reducing the production of stomach acid and allowing the oesophageal mucosa to heal.^[15][16] H2-receptor antagonists (such as famotidine) may be used as an alternative or adjunct in some cases.^[1][16] Alginates and antacids can also provide symptomatic relief and are often recommended alongside or between doses of other treatments per NICE CKS guidance.

For patients with confirmed hiatus hernia or severe oesophagitis that does not respond to medical management, surgical options such as laparoscopic fundoplication may be considered. This procedure reinforces the LOS to prevent reflux. NHS treatment decisions are guided by the severity of disease, response to medication and individual patient factors.

Alongside medication, NICE CG184 recommends addressing modifiable risk factors, including excess weight, dietary habits, smoking and alcohol consumption, as integral parts of oesophagitis management rather than optional additions.

Can losing visceral fat improve or reverse oesophagitis?

Losing visceral fat reduces intra-abdominal pressure and LOS dysfunction, leading to significant decreases in reflux frequency and severity. In mild to moderate oesophagitis, sustained weight loss may reduce or eliminate the need for long-term acid-suppressing medication.

Losing visceral fat can meaningfully improve oesophagitis symptoms and, in many cases, support healing of the oesophageal lining. Because visceral fat is a primary driver of elevated intra-abdominal pressure and LOS dysfunction, reducing it directly addresses the underlying mechanical cause of reflux-related oesophageal injury. Clinical studies and systematic reviews have demonstrated that weight loss, particularly reduction of central adiposity, is associated with significant decreases in reflux frequency and severity, even without achieving a normal BMI.^[18][5]

For individuals with mild to moderate oesophagitis, sustained weight loss combined with dietary and lifestyle modification may reduce or eliminate the need for long-term acid-suppressing medication. In those with more established disease, weight loss is unlikely to reverse structural changes such as Barrett's oesophagus, but it can slow progression and reduce symptom burden considerably.

It is worth noting that the approach to weight loss may influence outcomes. Programmes combining a calorie-controlled diet with regular aerobic exercise are associated with reductions in visceral fat. Evidence suggests that aerobic exercise contributes to visceral fat reduction, and combined aerobic and resistance training programmes are often most effective overall. Crash dieting or very low-calorie diets without medical supervision may not achieve lasting visceral fat reduction and can carry their own risks.

For people who are struggling to lose weight through lifestyle changes alone, clinically supervised weight management programmes are available on the NHS, including the NHS Digital Weight Management Programme. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a range of treatment options may be considered if clinically appropriate.

Lifestyle changes to reduce visceral fat and reflux

NICE CG184 recommends smaller meals, limiting fatty and trigger foods, at least 150 minutes of aerobic activity weekly, and elevating the head of the bed to reduce nocturnal reflux. Stopping smoking and avoiding eating within two to three hours of bedtime are also strongly advised.

UK clinical guidance, including NICE CG184 and NICE CKS for GORD in adults, recommends a combination of dietary modification, physical activity and behavioural change as the foundation for reducing visceral fat and managing GORD-related oesophagitis. These changes work together: reducing visceral fat lowers intra-abdominal pressure, while specific dietary adjustments reduce the frequency and acidity of reflux episodes.

Dietary recommendations include:

• Eating smaller, more frequent meals rather than large portions

• Limiting high-fat, fried or spicy foods if they worsen your symptoms, as triggers vary between individuals

• Reducing caffeine, alcohol and carbonated drinks, all of which can worsen reflux in many people

• Not eating within two to three hours of going to bed

• Maintaining adequate fibre intake to support healthy gut motility

Physical activity guidance: The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week for adults, such as brisk walking, cycling or swimming.^[20][21] Aerobic exercise is associated with reductions in visceral fat, and combined aerobic and resistance training programmes are often most effective. High-impact exercise immediately after eating should be avoided, as it can temporarily worsen reflux.

Behavioural and positional measures:

• Elevating the head of the bed by 15 to 20 centimetres can reduce nocturnal reflux, as supported by NICE CKS^[19]

• Sleeping on the left side has been associated with fewer reflux episodes in some studies, though evidence is limited

• Stopping smoking is strongly recommended, as nicotine relaxes the LOS

• Wearing loose-fitting clothing around the abdomen reduces external pressure on the stomach

These measures are most effective when sustained over time and tailored to the individual. If lifestyle changes alone are insufficient, a GP can review whether pharmacological or surgical options are appropriate alongside continued lifestyle support.

Scientific References

1. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184) – Recommendations.
2. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184) – Appendix A: Dosage information on proton pump inhibitors.
3. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184) – Appendix D: Evidence Tables [update 2014].
4. Suspected cancer: recognition and referral (NG12) – Recommendations organised by site of cancer.
5. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis.
6. Inflammatory cytokine profiles in visceral and subcutaneous adipose tissues of obese patients undergoing bariatric surgery reveal lack of correlation with obesity or diabetes.
7. Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumour necrosis factor-alpha in men.
8. Reappraisal of Adipose Tissue Inflammation in Obesity.
9. Message Transmission Between Adipocyte and Macrophage in Obesity.
10. Visseral Lipectomy Improves Metabolic Syndrome Parameters and Adipokines in a Rat Model of Metabolic Syndrome Induced by Monosodium Glutamate.
11. Causes of oesophageal cancer.
12. Barrett's oesophagus (NICE-commissioned review).
13. Natural history of Barrett's esophagus.
14. Erosive esophagitis is a risk factor for Barrett's esophagus: a community-based endoscopic follow-up study.
15. Effect of Omeprazole on Osteoblasts and Osteoclasts in vivo and in the in vitro Model Using Fish Scales.
16. History and Pharmacological Mechanism of Gastric Acid-suppressive Drugs.
17. Tegoprazan: a novel, highly selective, and potent potassium-competitive acid blocker (P-CAB).
18. Comparative Outcomes of Roux-en-Y Gastric Bypass and Fundoplication in Adults Living with Obesity and GERD: A Systematic Review and Meta-analysis.
19. Systematic review: Clinical effectiveness of interventions for the treatment of nocturnal gastroesophageal reflux.
20. UK Chief Medical Officers' Physical Activity Guidelines.
21. Physical activity guidelines for adults aged 19 to 64.
22. Effects of transdermal nicotine on lower esophageal sphincter and esophageal motility.
23. Disrupting the adiposopathy-inflammation loop: a translational immunometabolic framework for inflammatory disease.

Frequently Asked Questions